177172-49-5

中文名称 2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐

英文名称 2-Chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-benzenepropanaminehydrochloride

CAS 177172-49-5

分子式 C18H23Cl2NO

分子量 340.287

MOL 文件 177172-49-5.mol

更新日期 2023/12/27 09:22:15

177172-49-5 结构式

基本信息物理化学性质安全数据图谱信息 2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐价格(试剂级) 常见问题列表

基本信息

中文别名

2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐

英文别名

R-568
R 568 hydrochloride
Tecalcet (Hydrochloride)
R-568 hydrochloride >=95% (HPLC)
2-Chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-benzenepropanaminehydrochloride
(R)-3-(2-Chlorophenyl)-N-(1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride
3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine, hydrochloride
Benzenepropanamine, 2-chloro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-, hydrochloride (1:1)

物理化学性质

熔点183.3-184.4 °C

储存条件Inert atmosphere,Room Temperature

溶解度DMSO : 50 mg/mL (146.93 mM; Need ultrasonic)

形态粉末

颜色White to off-white

旋光度 (Optical Rotation)[α]/D +35 to +40°, c =0.5 in chloroform-d

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS07

警示词警告

危险性描述H302-H315-H319-H335

防范说明P261-P305+P351+P338

图谱信息

2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐(177172-49-5)核磁图(¹HNMR)

2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/05/22	HY-10167A	2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐 Tecalcet Hydrochloride	177172-49-5	1 mg	335元
2025/05/22	HY-10167A	2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐 Tecalcet Hydrochloride	177172-49-5	5mg	938元
2025/05/22	HY-10167A	2-氯-N-[(1R)-1-(3-甲氧基苯基)乙基]苯丙胺盐酸盐 Tecalcet Hydrochloride	177172-49-5	10mg	1500元

常见问题列表

生物活性

Tecalcet Hydrochloride (R 568 Hydrochloride) 是一个口服有效的拟钙剂，变构正调控钙敏感受体 (CaSR)。Tecalcet Hydrochloride (R 568 Hydrochloride) 可提高激活细胞外Ca2+的敏感性。

体外研究

Tecalcet (NPS 568, 0.1-100 μM) increase [Ca ²⁺ ]i in a concentrationdependent and stereoselective manner.
Tecalcet (NPS 568, 0.1-100 nM) shiftes the concentration-response curve for extracellular Ca ²⁺ to the left without affecting the maximal response and, thereby, decreases the EC ₅₀ value for extracellular Ca21 to 0.61±0.04 mM.

体内研究

Tecalcet (1.5 and 15 mg/kg, orally, twice daily for 4 days) inhibits PT cell proliferation in rats with renal insufficiency.

Animal Model:	10-wk-old Male Sprague-Dawley rats weighing 310-350 g.
Dosage:	1.5 and 15 mg/kg.
Administration:	Orally twice daily for 4 days.
Result:	Did not significantly change serum 1,25 (OH) ₂ D ₃ levels. In contrast, serum PTH levels were reduced by in a dose-dependent manner. Clearly reduced the number of BrdU-positive PT cells by 20% at a low dose (1.5 mg/kg body wt), and by 50% at a high dose (15 mg/kg body wt), indicating an antiproliferative effect on PT cells. Reduced PT cell volume in a dose-dependent manner.